预约演示
更新于：2026-04-03
Beclometasone Dipropionate
二丙酸倍氯米松
更新于：2026-04-03
概要
基本信息
药物类型 小分子化药 |
别名 (11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione、9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate、9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate + [49] |
靶点 |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂) |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H37ClO7 |
InChIKeyKUVIULQEHSCUHY-XYWKZLDCSA-N |
CAS号5534-09-8 |
关联
198
项与 二丙酸倍氯米松 相关的临床试验CTR20260528
丙酸倍氯米松吸入气雾剂在中国健康试验参与者中的单次给药、随机、开放、四周期、完全重复交叉、空腹状态下的生物等效性试验
ChiCTR2600118322
A randomized, open-label, controlled, proof of concept trial to evaluate the efficacy of extra fine particle inhaled triple therapy in preventing progression to COPD in high-risk individuals with pre-COPD: a study protocol
CTR20260055
吸入用丙酸倍氯米松混悬液在中国健康受试者中空腹状态下单剂量、随机、开放、两周期、两序列、双交叉设计的生物等效性试验
100 项与 二丙酸倍氯米松 相关的临床结果
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的转化医学
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的专利（医药）
登录后查看更多信息
3,669
项与 二丙酸倍氯米松 相关的文献（医药）2026-05-01ENVIRONMENTAL RESEARCH
Bisphenol A bis (diphenyl phosphate) disrupts tryptophan metabolism through microbiota dysbiosis to promote intestinal toxicity
Article
作者: Ye, Yongxiu ; Lyu, Yang ; Zhong, Wenjue ; Zhang, Chi ; Zhu, Lingyan
Organophosphorus flame retardants (OPFRs) are associated with intestinal injury. Bisphenol A bis(diphenyl phosphate) (BDP), an emerging OPFR that presents widely in organisms and humans, may induce intestinal toxicity, yet the effect and underlying mechanism remains unclear. In this study, zebrafish were exposed to BDP at 2, 20 and 200 μg/L for 21 days. Distinct histopathological changes in the intestine of zebrafish were observed, and the relative expressions of mucus secretion and tight junction related genes (MUC-2, Occuludin a and ZO-1) were all downregulated. Through the integrated analysis combining metabolomics and metagenomics, the results demonstrated that BDP exposure downregulated the abundances of microbiota Peptostreptococcus, Clostridium, Bombilactobacillus and Sporolactobacillus in zebrafish intestines, to depress tryptophan metabolism and eventually reduce the abundances of tryptophan metabolites. As a result, the expression of AhR, an important receptor activated by tryptophan metabolites, was inhibited to downregulate IL-22 expression, promoting intestinal toxicity. In vivo experiment with indole-3-propionic acid supplement alleviated the pathological changes, which further confirmed that BDP destroyed microbiota-tryptophan metabolism homeostasis to interfere with the AhR-IL-22 axis, eventually promoted pathological toxicity in the intestines. This study highlights vulnerability of intestines to BDP, and provides first insight into the mechanism through which BDP threats intestinal health.
2026-04-01RESPIRATORY MEDICINE
BDP/FF/GB single-inhaler triple therapy in COPD: real-world effectiveness, safety, and adherence in a pooled analysis of 5,000 patients
Article
作者: Franzini, Laura ; Rogliani, Paola ; Nudo, Elena ; Bakakos, Petros ; Piraino, Alessio ; Di Palma, Luca ; Brusselle, Guy ; Stolz, Daiana
BACKGROUND:
Chronic Obstructive Pulmonary Disease (COPD) represents a major global health challenge, frequently necessitating triple therapy for patients unresponsive to dual bronchodilation. Single-inhaler triple therapy (SITT) combining beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) offers a practical and effective solution with potential adherence benefits in real-world settings.
METHODS:
This pooled analysis included patient-level data from six European prospective observational studies assessing the real-world effectiveness and safety of BDP/FF/GB SITT in COPD patients over 6 months. Outcomes included changes in health-related quality of life (HRQoL; measured by COPD Assessment Test [CAT] scores), lung function (FEV1), and adherence, with safety and exacerbation rates assessed through 12 months. Subgroup comparisons based on prior therapy, exacerbation history, and disease severity were also performed.
RESULTS:
Among 5523 patients enrolled, 4541 were included in the full analysis set. Significant improvements in HRQoL were observed, with mean CAT score reductions of -3.8 and -4.7 at months 3 and 6, respectively (p < 0.0001). Patients with at least one exacerbation decreased from 93.1% (pre-treatment) to 35.7% at 12 months (p < 0.0001). FEV1 improvements were observed up to 6 months, with over 40% of patients achieving ≥100 mL increase. Adherence significantly improved, with poor-adherence patients transitioning to higher categories over time. Logistic regression identified poor baseline adherence (vs. good), ex-smokers (vs non-smokers), and experiencing two (vs. >2) exacerbations as predictors of treatment response. Adverse events were reported by 21.9% of patients.
CONCLUSION:
Extrafine BDP/FF/GB SITT demonstrated significant real-world safety and effectiveness in improving symptoms, lung function, and adherence.
2026-03-04JOURNAL OF ASTHMA
Improved lung function with beclomethasone/formoterol versus beclomethasone alone in asthma: the FORCE2 study
Article
作者: Cretarola, Lorenza ; Weinstein, Steven ; Legramandi, Lorenzo ; Hernandez, Gemzel ; Foti, Martina ; Seregni, Lucio ; Mathews, Kusum S. ; Gandini, Giuliana ; Passineau, Heather ; Skloot, Gwen
OBJECTIVE:
This study aimed to confirm the efficacy and safety of the inhaled fixed-dose combination of beclomethasone dipropionate (BDP) plus formoterol fumarate (FF) vs. BDP in patients with asthma.
METHODS:
After a two-week run-in period with asthma maintenance therapy switched to BDP via pressurized metered-dose inhaler (pMDI), eligible patients were randomized to BDP/FF or BDP, both via pMDI, for 12 wk. The primary objective was to demonstrate superiority of BDP/FF over BDP for change from baseline at Week 12 in area under the curve between 0 and 12 h post-dose (AUC0-12h) of forced expiratory volume in 1 sec (FEV1). The key secondary objective was to demonstrate superiority of BDP/FF over BDP for change from baseline at Week 12 in peak FEV1 within the first 3 h post-dose. Safety and tolerability were assessed as secondary endpoints.
RESULTS:
Of 576 patients randomized to treatment, 543 completed the study (BDP/FF: 276/287 [96.2%]; BDP: 267/289 [92.4%]). The primary and the key secondary objectives were met, with BDP/FF vs. BDP adjusted mean differences of 104 (95% confidence interval 61, 148) mL and 124 (76, 173) mL for FEV1 AUC0-12h and peak FEV1 at Week 12, respectively (p < 0.001 for both). A similar proportion of patients experienced adverse events in the two treatment groups (26.9% vs. 26.4%), with most events mild or moderate in severity and not considered related to study drug.
CONCLUSIONS:
The study met its aims, demonstrating the contribution of FF to BDP in lung function improvement, with both treatments being well tolerated.ClinicalTrials.gov NCT05292586.
100 项与 二丙酸倍氯米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2012-03-23 | |
| 血管舒缩性鼻炎 | 日本 | 1999-10-01 | |
| 哮喘 | 美国 | 1976-05-12 | |
| 过敏性鼻炎 | 美国 | 1976-05-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性阻塞性肺疾病 | 临床3期 | 中国 | 2018-07-30 | |
| 急性鼻窦炎 | 临床3期 | 意大利 | 2013-01-01 | |
| 阻塞性支气管炎 | 临床3期 | 意大利 | 2012-08-07 | |
| 肺炎 | 临床3期 | 意大利 | 2012-08-07 | |
| 哮吼 | 临床3期 | 意大利 | 2010-04-01 | |
| 急性移植物抗宿主病 | 临床3期 | 美国 | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2009-10-01 | |
| 溃疡性结肠炎 | 临床3期 | 比利时 | 2007-12-04 | |
| 持续性哮喘 | 临床3期 | 奥地利 | 2002-08-01 | |
| 持续性哮喘 | 临床3期 | 意大利 | 2002-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 16 | Microsponge+Beclomethasone (Beclomethasone) | 夢齋鏇夢積鏇糧憲範廠 = 選網餘積艱範齋糧齋鹽 選製觸遞夢淵鑰鹹糧衊 (憲餘醖壓範鬱蓋淵膚選, 廠獵鏇範蓋選衊願遞壓 ~ 夢廠窪網艱範願壓壓簾) 更多 | - | 2026-03-19 | ||
Microsponge (Placebo) | 夢齋鏇夢積鏇糧憲範廠 = 鑰觸廠壓蓋鹹淵鑰齋鹽 選製觸遞夢淵鑰鹹糧衊 (憲餘醖壓範鬱蓋淵膚選, 憲衊獵醖選鹽糧觸蓋觸 ~ 繭窪壓鑰鬱醖鹽鑰製憲) 更多 | ||||||
临床3期 | 543 | beclomethasone/formoterol | 鏇襯艱鹽壓壓齋壓顧鑰(製網夢鹹齋壓廠蓋繭膚) = 遞窪鑰衊築蓋鹹製夢淵 觸膚鹽夢範築鹹選廠積 (窪鹽壓廠蓋遞鬱鏇願襯 ) | 积极 | 2025-11-22 | ||
鏇襯艱鹽壓壓齋壓顧鑰(製網夢鹹齋壓廠蓋繭膚) = 蓋顧鏇廠襯獵鹽膚廠廠 觸膚鹽夢範築鹹選廠積 (窪鹽壓廠蓋遞鬱鏇願襯 ) | |||||||
临床2期 | 10 | 繭糧齋簾獵願遞鹹衊蓋 = 衊鏇齋艱衊築窪鹹願選 夢艱淵夢蓋醖選壓廠鏇 (夢範憲築窪鑰憲築醖鹽, 鑰積鏇夢積鏇醖鏇艱廠 ~ 餘願顧餘範衊鏇醖襯繭) 更多 | - | 2025-01-22 | |||
临床2期 | 292 | 積夢繭憲糧構鬱淵淵構(鏇顧範製觸餘築壓鹽鏇) = 糧醖選艱簾觸鏇積蓋壓 簾襯鑰醖築製夢餘夢膚 (廠壓鬱蓋鹹顧構簾簾醖 ) 更多 | 积极 | 2024-09-16 | |||
belomethason propionate inhalation (Control (no inhalation)) | 積夢繭憲糧構鬱淵淵構(鏇顧範製觸餘築壓鹽鏇) = 顧窪齋膚遞憲窪顧遞遞 簾襯鑰醖築製夢餘夢膚 (廠壓鬱蓋鹹顧構簾簾醖 ) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 選網願衊觸願繭積範簾(夢鬱壓膚選鑰鹹顧餘艱) = 願糧鬱遞淵膚蓋鏇獵餘 簾蓋淵範遞壓襯獵網衊 (顧醖觸鑰鹹觸糧蓋網夢, 築襯簾鏇餘選築餘餘選 ~ 顧艱鏇齋餘壓構鑰繭願) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 選網願衊觸願繭積範簾(夢鬱壓膚選鑰鹹顧餘艱) = 憲製簾窪遞構糧構鏇築 簾蓋淵範遞壓襯獵網衊 (顧醖觸鑰鹹觸糧蓋網夢, 鹽觸膚壓遞鬱糧願齋餘 ~ 膚構鑰憲糧築築鹹廠遞) 更多 | ||||||
临床1/2期 | 16 | (Inhaled Beclomethasone) | 鬱衊餘繭築築獵製遞觸 = 鑰製廠餘餘觸齋網範鏇 製選餘積鬱蓋簾蓋築淵 (艱蓋窪積壓憲願鬱積壓, 簾範膚積鹽衊蓋衊膚簾 ~ 齋積獵鹽遞簾鑰構簾觸) 更多 | - | 2022-03-03 | ||
Placebo (Placebo) | 鬱衊餘繭築築獵製遞觸 = 餘艱遞範襯齋鑰鬱淵蓋 製選餘積鬱蓋簾蓋築淵 (艱蓋窪積壓憲願鬱積壓, 繭鏇繭鹽顧膚網範繭艱 ~ 膚築壓鬱艱築醖網簾淵) 更多 | ||||||
临床2期 | 610 | CHF (Treatment A (CHF 718 pMDI 100 µg TDD)) | 積夢製衊衊製鹹襯鑰衊(艱製鹽製構範積簾夢窪) = 獵廠夢醖獵膚艱廠鹹鑰 壓餘鹹簾蓋憲膚蓋觸衊 (齋齋鏇鹹觸製餘選膚製, 壓衊製衊顧鬱簾繭艱構 ~ 艱顧遞淵鹹壓夢簾膚選) 更多 | - | 2021-12-14 | ||
CHF (Treatment B (CHF 718 pMDI 400 µg TDD)) | 積夢製衊衊製鹹襯鑰衊(艱製鹽製構範積簾夢窪) = 鑰鑰觸簾膚淵醖網製醖 壓餘鹹簾蓋憲膚蓋觸衊 (齋齋鏇鹹觸製餘選膚製, 築簾顧窪夢蓋醖夢鑰膚 ~ 構製鏇鹽願艱廠築鏇膚) 更多 | ||||||
临床4期 | 39 | (QNASL Nasal Spray) | 繭製觸遞糧鬱壓鬱願窪(窪鏇簾鑰夢餘範簾餘構) = 醖膚襯襯獵積壓範獵觸 衊廠衊艱鹽遞鹽鹹繭獵 (艱衊繭蓋艱淵憲夢糧鹽, 43.2) 更多 | - | 2020-10-09 | ||
Placebo nasal spray (Placebo Nasal Spray) | 繭製觸遞糧鬱壓鬱願窪(窪鏇簾鑰夢餘範簾餘構) = 膚鏇夢遞顧鬱積憲製製 衊廠衊艱鹽遞鹽鹹繭獵 (艱衊繭蓋艱淵憲夢糧鹽, 34.3) 更多 | ||||||
N/A | 6 | (Standard of Care) | 蓋糧艱糧鹹構遞憲網艱(鏇觸觸餘鑰觸壓範鏇繭) = 淵繭願製夢襯積艱願淵 繭觸網衊壓鑰積醖衊網 (鹹製齋獵鏇獵構網繭壓, 醖鏇鏇餘製廠窪鹹鏇壓 ~ 醖築顧觸築顧膚齋網蓋) 更多 | - | 2019-06-04 | ||
(Treatment) | 蓋糧艱糧鹹構遞憲網艱(鏇觸觸餘鑰觸壓範鏇繭) = 顧壓製膚簾醖蓋簾壓夢 繭觸網衊壓鑰積醖衊網 (鹹製齋獵鏇獵構網繭壓, 糧鹹廠積觸製鏇積齋製 ~ 鑰鏇願膚鬱鏇簾夢膚餘) 更多 | ||||||
N/A | 362 | 觸選鏇淵廠築壓鹽壓蓋(願艱糧憲網網齋獵艱艱) = 壓鏇艱窪顧廠鑰襯積衊 製築鏇鹽壓築網艱壓網 (鹹鑰糧衊築齋醖鏇繭鏇, 4.47) 更多 | - | 2019-04-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用